Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Conditions
- GanglioneuroblastomaNeuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyRadiation: External Beam Radiation TherapyRadiation: Iobenguane I-123Radiation: Iobenguane I-131Procedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 724
- Registration Number
- NCT03126916
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma
- Conditions
- High Risk Neuroblastoma
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT03061656
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
- Conditions
- Hematologic Malignancy
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02880293
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)
- Conditions
- Retinoblastoma
- Interventions
- Radiation: Orbital irradiationOther: ObservationProcedure: CytapheresisProcedure: Peripheral bood stem cell transplantation
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 185
- Registration Number
- NCT02870907
- Locations
- 🇫🇷
Chr Felix Guyon, Saint-Denis, La Réunion, France
🇫🇷Hopital Nord Chu Amiens, Amiens, France
🇫🇷Chu Angers, Angers, France
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseGraft Versus Host Disease
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Monica Bhatia
- Target Recruit Count
- 24
- Registration Number
- NCT02867800
- Locations
- 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- Conditions
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent High Risk Myelodysplastic SyndromeRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Lymphoblastic LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Plasma Cell MyelomaHigh Risk Acute Myeloid LeukemiaLymphoproliferative Disorder
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT02861417
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
- Conditions
- Myeloid SarcomaChronic Myeloid Leukemia (CML)Myelodysplastic Syndrome (MDS)Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Non-Hodgkin Lymphoma (NHL)Juvenile Myelomonocytic Leukemia (JMML)
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02790515
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
- Conditions
- Intracranial Non-germinomatous Germ Cell Tumor
- Interventions
- Radiation: Reduced dose radiotherapy
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02784054
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma
- Conditions
- Unresectable Localized Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT02784015
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
- Conditions
- Sickle Cell Disease
- Interventions
- Procedure: Bone Marrow Transplant (BMT)Other: Rabbit Anti-thymocyte GlobulinRadiation: Total Body Irradiation
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 10
- Registration Number
- NCT02757885
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.